Comprehensive staging of newly diagnosed lung cancer: prospective multi-centre comparison of whole body Magnetic Resonance Imaging with standard diagnostic imaging pathways

niversity College London (UK)0 个研究点目标入组 353 人开始时间: 2012年7月31日最近更新: 2020年1月21日

适应症

试验速览

2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31080129 (added 14/05/2019) 2019 results against ISRCTN43958015 in: https://www.ncbi.nlm.nih.gov/pubmed/31855148 (added 20/12/2019)

•1. Adult patients (18 or over) with histologically proven or clinically diagnosed primary non small cell lung cancer with potentially radically treatable disease
•2. Clinically diagnosed non small cell lung cancer defined as radiological diagnosis of lung cancer on chest CT with sufficient confidence to trigger staging investigations
•3. Potentially radically treatable disease defined as stage IIIb or less on diagnostic CT (ie T14, N02, M0)
•4. Performance status 02 (fit to undergo surgery if indicated)
•5. Patient must have given written informed consent and be willing to comply with the protocol intervention and follow up.

•1. Any psychiatric or other disorder likely to impact on informed consent
•2. Evidence of severe or uncontrolled systemic disease which make it undesirable the for the patient to participate in the trial
•3. Pregnancy
•4. Contraindications to MRI (e.g. cardiac pacemaker, severe claustrophobia, inability to lie flat)
•5. Unequivocal metastatic or N3 disease on diagnostic CT chest and abdomen (including M1a disease; malignant pleural effusion)
•6. Further staging work up not indicated in the opinion of the MDT due to poor performance status or patient choice.
•7. Histologies other than non small cell lung cancer

发起方

niversity College London (UK)